S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:CLVS

Clovis Oncology Stock Forecast, Price & News

$5.58
-0.08 (-1.41 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.04
Now: $5.58
$5.78
50-Day Range
$5.55
MA: $7.23
$10.34
52-Week Range
$3.62
Now: $5.58
$11.10
Volume8.70 million shs
Average Volume9.28 million shs
Market Capitalization$583.28 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Clovis Oncology logo

Headlines

Clovis Oncology: Q4 Earnings Insights
February 23, 2021 |  finance.yahoo.com
Clovis Oncology Announces 2020 Operating Results
February 23, 2021 |  finance.yahoo.com
Clovis Oncology, Inc. to Host Earnings Call
February 23, 2021 |  finance.yahoo.com
Earnings Preview for Clovis Oncology
February 22, 2021 |  finance.yahoo.com
4 Top Stock Trades for Tuesday: HAS, CLVS, XPEV, NLS
February 8, 2021 |  investorplace.com
Koss Investors Hear the Sound of a Short Squeeze
January 26, 2021 |  thestreet.com
CLVS Jul 2021 10.000 call
January 2, 2021 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.01 million
Book Value($3.17) per share

Profitability

Net Income$-400,420,000.00
Net Margins-230.34%

Miscellaneous

Market Cap$583.28 million
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

634th out of 1,972 stocks

Pharmaceutical Preparations Industry

296th out of 772 stocks

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$5.58
-0.08 (-1.41 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

Is Clovis Oncology a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Clovis Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View analyst ratings for Clovis Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Clovis Oncology?

Wall Street analysts have given Clovis Oncology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Clovis Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Clovis Oncology
.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) posted its quarterly earnings data on Monday, February, 22nd. The biopharmaceutical company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.26.
View Clovis Oncology's earnings history
.

How has Clovis Oncology's stock price been impacted by COVID-19 (Coronavirus)?

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLVS stock has decreased by 9.6% and is now trading at $5.58.
View which stocks have been most impacted by COVID-19
.

What guidance has Clovis Oncology issued on next quarter's earnings?

Clovis Oncology issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $43-43.5 million, compared to the consensus revenue estimate of $39.86 million.

What price target have analysts set for CLVS?

6 equities research analysts have issued 12 month price targets for Clovis Oncology's stock. Their forecasts range from $3.00 to $17.00. On average, they expect Clovis Oncology's share price to reach $8.80 in the next twelve months. This suggests a possible upside of 57.7% from the stock's current price.
View analysts' price targets for Clovis Oncology
or view top-rated stocks among Wall Street analysts.

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the following people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Clovis Oncology's key competitors?

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (2.16%), Northern Trust Corp (1.10%), Pinnacle Associates Ltd. (0.80%), Candriam Luxembourg S.C.A. (0.60%), Panagora Asset Management Inc. (0.53%) and Bank of New York Mellon Corp (0.48%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross, Thomas C Harding and Thorlef Spickschen.
View institutional ownership trends for Clovis Oncology
.

Which institutional investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Principal Financial Group Inc., SG Americas Securities LLC, Pinnacle Associates Ltd., Caption Management LLC, Northern Trust Corp, Aperio Group LLC, and Alliancebernstein L.P.. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, and Thomas C Harding.
View insider buying and selling activity for Clovis Oncology
or view top insider-selling stocks.

Which institutional investors are buying Clovis Oncology stock?

CLVS stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Virginia Retirement Systems ET AL, Squarepoint Ops LLC, Panagora Asset Management Inc., Bank of New York Mellon Corp, LPL Financial LLC, ProShare Advisors LLC, and GSA Capital Partners LLP. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen.
View insider buying and selling activity for Clovis Oncology
or or view top insider-buying stocks.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $5.58.

How much money does Clovis Oncology make?

Clovis Oncology has a market capitalization of $583.28 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

Where are Clovis Oncology's headquarters?

Clovis Oncology is headquartered at 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.